Identification of the methylation of p14ARF promoter as a novel non-invasive biomarker for early detection of lung cancer

Clinical and Translational Oncology

Volumn 16, Issue 6, 2014, Pages 581-589

  Li, L ^a   Shen, Y ^a   Wang, M ^a   Tang, D ^a   Luo, Y ^a   Jiao, W ^a   Wang, Z ^a   Yang, R ^a   Tian, K ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Epigenetic change lung cancer; NMSPCR; p14ARF promoter methylation

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; TUMOR MARKER;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON INVASIVE PROCEDURE; PROBABILITY; PROMOTER REGION; PROTEIN BLOOD LEVEL; SURVIVAL TIME; ADENOCARCINOMA; BLOOD; CANCER STAGING; DNA METHYLATION; GENETICS; LUNG TUMOR; MIDDLE AGED; MORTALITY; NON SMALL CELL LUNG CANCER; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA METHYLATION; DNA, NEOPLASM; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 84901587771     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-013-1122-1     Document Type: Article

References (26)

1. Seder CW, Allen MS, Cassivi SD, Deschamps C, Nichols FC, Olivier KR, et al. Stage III A non-small cell lung cancer: morbidity and mortality of three distinct multimodality regimens. Ann Thorac Surg. 2013;95:1708-16.
2. Hirsh V. Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer. Clin Lung Cancer. 2009;10:223-9.
3. Shapiro M, Mhango G, Kates M, Weiser TS, Chin C, Swanson SJ, et al. Extent of lymph node resection does not increase perioperative morbidity and mortality after surgery for stage I lung cancer in the elderly. Eur J Surg Oncol. 2012;38:516-22.
4. Hamaji M, Allen MS, Cassivi SD, Deschamps C, Nichols FC, Wigle DA, et al. Surgical treatment of metachronous second primary lung cancer after complete resection of non-small cell lung cancer. J Thorac Cardiovasc Surg. 2013;145: 683-90 (discussion 90-1).
5. Shimada Y, Saji H, Yoshida K, Kakihana M, Honda H, Nomura M, et al. Pathological vascular invasion and tumor differentiation predict cancer recurrence in stage IA non-small-cell lung cancer after complete surgical resection. J Thorac Oncol. 2012;7:1263-70.
6. Tessema M, Willink R, Do K, Yu YY, Yu W, Machida EO. Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25. Cancer Res. 2008;68:1707-14. (Pubitemid 351416555)
7. Nikolaidis G, Raji OY, Markopoulou S, Gosney JR, Bryan J, Warburton C, et al. DNA methylation biomarkers offer improved diagnostic efficiency in lung cancer. Cancer Res. 2012;72:5692-701.
8. Kalari S, Jung M, Kernstine KH, Takahashi T, Pfeifer GP. The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells. Oncogene. 2012;32:3559-68.
9. Eisenberg-Lerner A, Kimchi A. DAPk silencing by DNA methylation conveys resistance to anti EGFR drugs in lung cancer cells. Cell Cycle. 2012;11:2051.
10. Walter K, Holcomb T, Januario T, Du P, Evangelista M, Kartha N, et al. DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer. Clin Cancer Res. 2012;18:2360-73.
11. Ostrow KL, Hoque MO, Loyo M, Brait M, Greenberg A, Siegfried JM, et al. Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin Cancer Res. 2010;16:3463-72.
12. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821-6. (Pubitemid 26296693)
13. Zemaitis M, Rieger N, Fischer JR, Sakalauskas R, Malakauskas K, Lahm H. [Aberrant promoter methylation of tumor suppressor genes in serum from lung cancer patients: frequency and correlation with clinicopathological characteristics]. Medicina (Kaunas). 2005;41:123-31.
14. Kim DH, Nelson HH, Wiencke JK, Zheng S, Christiani DC, Wain JC, et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res. 2001;61:3419-24. (Pubitemid 32695035)
15. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001;61:249-55. (Pubitemid 32095725)
16. Sanchez-Cespedes M, Reed AL, Buta M, Wu L, Westra WH, Herman JG, et al. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer. Oncogene. 1999;18:5843-9. (Pubitemid 29520440)
17. Sato M, Horio Y, Sekido Y, Minna JD, Shimokata K, Hasegawa Y. The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines. Oncogene. 2002;21:4822-9. (Pubitemid 34879457)
18. Bria E, Bonomi M, Pilotto S, Massari F, Novello S, Levra MG. Clinical meta-analyses of targeted therapies in adenocarcinoma. Target Oncol. 2013;8:35-45.
19. Gupta R, Dastane AM, McKenna R Jr, Marchevsky AM. The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: reviewof current "best evidence" with meta-analysis. Hum Pathol. 2009;40:356-65.
20. Kim DS, Kim MJ, Lee JY, Kim YZ, Kim EJ, Park JY. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features. Cancer. 2007;110:2785-92.
21. Kim JS, Kim JW, Han J, Shim YM, Park J, Kim DH. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res. 2006;66:4049-54.
22. Kim JS, Han J, Shim YM, Park J, Kim DH. Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma. Cancer. 2005;104:1825-33. (Pubitemid 41513164)
23. Buckingham L, Penfield Faber L, Kim A, Liptay M, Barger C, Basu S, et al. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer. 2010;126:1630-9.
24. Kim DH, Kim JS, Park JH, Lee SK, Ji YI, Kwon YM, et al. Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer. Cancer Res. 2003;63:6206-11. (Pubitemid 37255165)
25. Lee HJ, Seol HS, Kim JY, Chun SM, Suh YA, Park YS, et al. ROS1 receptor tyrosine kinase, a druggable target, is frequently overexpressed in non-small cell lung carcinomas via genetic and epigenetic mechanisms. Ann Surg Oncol. 2013;20:200-8.
26. Lee SM, Park JY, Kim DS. Methylation of TMEFF2 gene in tissue and serum DNA from patients with non-small cell lung cancer. Mol Cells. 2012;34:171-6.